These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23917376)

  • 1. Uncovering the genetic landscape driving castration-resistant prostate cancer.
    Martin TJ; Peer CJ; Figg WD
    Cancer Biol Ther; 2013 May; 14(5):399-400. PubMed ID: 23917376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutational landscape of lethal castration-resistant prostate cancer.
    Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
    Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
    Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
    Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
    Wang Z; Yan X; Tang P; Tang T; Wang Y; Peng S; Wang S; Lan W; Wang L; Zhang Y; Zhang J; Li K; Shu Z; Xu J; Qin J; Zhang D; Jiang J; Liu Q
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):180-187. PubMed ID: 36401126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.
    Jiang Y; Palma JF; Agus DB; Wang Y; Gross ME
    Clin Chem; 2010 Sep; 56(9):1492-5. PubMed ID: 20581083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Fujimoto N; Naito S
    Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.
    Zhang C; Wang L; Wu D; Chen H; Chen Z; Thomas-Ahner JM; Zynger DL; Eeckhoute J; Yu J; Luo J; Brown M; Clinton SK; Nephew KP; Huang TH; Li W; Wang Q
    Cancer Res; 2011 Nov; 71(21):6738-6748. PubMed ID: 21900400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
    Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
    J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.